Exelixis, Inc. (EXEL) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended April 3, 2026 (referred to as March 31, 2026, for convenience). Exelixis is an oncology company focused on the discovery, development, and commercialization of medicines for difficult-to-treat cancers. Its revenue is primarily driven by the cabozantinib franchise (CABOMETYX and COMETRIQ), with a growing pipeline including the lead asset zanzalintinib, which is currently under FDA review for colorectal cancer.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $610.8 million | $555.4 million |
| Net Product Revenues | $555.0 million | $513.3 million |
| Collaboration Revenues | $55.8 million | $42.2 million |
| Net Income | $210.5 million | $159.6 million |
| Diluted EPS | $0.79 | $0.55 |
| Operating Cash Flow | $251.8 million | $211.4 million |
| Cash & Marketable Securities | $1.43 billion | $1.66 billion (Dec 31, 2025) |
| Effective Tax Rate | 21.4% | 22.4% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10% year-over-year. Net product revenues rose 8%, driven by a 7% increase in CABOMETYX unit sales (notably in combination with nivolumab for RCC and in NET indications) and a 1% increase in average net selling price.
- Collaboration Revenue: Increased 32% to $55.8 million, primarily due to a $7.7 million commercial milestone payment from Takeda upon achieving $300 million in cumulative net sales in Japan, and higher royalties from Ipsen.
- Profitability: Net income increased 32% to $210.5 million. Operating expenses decreased slightly (6% reduction in R&D, 2% increase in SG&A), contributing to higher operating income of $251.3 million.
- Liquidity: Cash and marketable securities decreased by approximately $236 million from the prior quarter end, primarily due to $430.4 million in stock repurchases and operating expenditures, partially offset by strong operating cash flow.
Guidance, Outlook, and Risks
- Pipeline Milestones: The FDA accepted the New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer, with a PDUFA target action date of December 3, 2026. Positive top-line results were announced for the STELLAR-303 trial showing a 20% reduction in risk of death versus regorafenib.
- Capital Allocation: The company repurchased $430.4 million of common stock in Q1 2026. In May 2026, the Board authorized an additional $750 million repurchase program through December 31, 2027.
- Outlook: Management projects net product revenues may increase for the remainder of 2026. R&D expenses are expected to increase due to expanded clinical trials for zanzalintinib and biotherapeutics (XB010, XB628, XB371).
- Risks: Significant litigation risks remain regarding generic competition for CABOMETYX (MSN, Sun, Azurity, Handa). While Sun settled in December 2025, consolidated litigation with MSN and Azurity is scheduled for trial in November 2026. Additionally, potential impacts from U.S. healthcare policy changes (IRA, MFN pricing proposals) and tariffs on imported pharmaceuticals are noted.
Investor Verification Checklist
- Patent Litigation Status: Verify the timeline and potential outcomes of the consolidated MSN and Azurity litigation, which could impact CABOMETYX exclusivity as early as 2030 or later depending on appeals.
- Zanzalintinib NDA Review: Monitor the FDA review process for the zanzalintinib NDA (PDUFA date: Dec 3, 2026) and the final analysis of the STELLAR-303 trial expected in mid-2026.
- Stock Repurchase Execution: Track the execution of the new $750 million repurchase program authorized in May 2026 and its impact on share count and liquidity.
- Regulatory Policy Impact: Assess the potential financial impact of proposed U.S. tariffs on imported pharmaceuticals and the "Most Favored Nation" pricing pilot programs on future net product revenues.